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Dear Sirs,
Schizophrenia is a common, heterogenous and complex
disorder with unknown aetiology [1]. There is established
evidence for N-methyl-D-aspartate receptor (NMDAR)
hypofunction [2] as a central component of the functional
dysconnectivity that is the most accepted model for
symptoms [3], and increasing evidence for potassium
channel dysfunction [4]. Moreover, autoimmune mecha-
nisms have been proposed, perhaps in subgroups of
patients [5, 6]. In the last few years, antibodies to neuronal
cell surface antigens have been identiﬁed in cases of
autoimmune encephalitis that respond to immunotherapy
[7, 8]. Over two-thirds of patients with NMDAR antibody
encephalitis, and some with potassium channel antibody-
associated limbic encephalitis, have prominent psychiatric
symptoms, or may present to psychiatric services in the
ﬁrst instance [7, 9, 10]. The psychiatric symptoms are those
seen in schizophrenia including delusions, hallucinations,
and catatonic movement disorder. There is good evidence for
speciﬁcityandpathogenicityoftheseantibodies,withabsence
in large numbers of healthy individuals and those with other
neurologicaldiseases[9,11,12].However,therehavebeenno
cases of NMDAR or potassium channel antibodies identiﬁed
inpatientswithpurelypsychiatricdisorders.Wehypothesized
that these antibodies would be present in a proportion of
patients with early schizophrenia, in the absence of overt
seizures, movement disorders, or other neurological signs.
Serum was obtained prospectively from a cohort
(n = 46) of patients at ﬁrst presentation of psychosis to an
epidemiologically principled early intervention for psy-
chosis service (http://www.cameo.nhs.uk), which provides
3 years of treatment and follow up when possible. We
retrospectively measured NMDAR antibodies using a cell
based assay and subjective visual scoring system [9]. We
identiﬁed antibodies to components of potassium channel
complexes (VGKCs) by radioimmunoassay [8]. The sera
were tested blind to diagnostic status. Patients with positive
results were retrospectively interviewed and extensively
investigated. Full clinical details are given in the Table and
supplementary information.
Patients 1 and 2 had NMDAR antibodies, [patient 1:
score 2, (range 0–4, normal 0–0.5, Fig. 1); patient 2: score
1]. Patient 1 was unwell for 6 months before recovering; he
was well and antibody negative at 3 years. Patient 2 has
had a protracted course; antibodies remained repeatedly
positive at 24–35 months follow up, but were then negative
at 36 months. Patient 3 had VGKC antibodies (1,435 pM;
normal\100), was unwell for 6 months before recovering,
but has subsequently relapsed after 1 year and has now
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differentiate these cases from other cases of psychosis in
Cameo (Table 1), even in retrospect, and the autoantibody
positive cases fulﬁlled criteria for DSM-IV schizophrenia.
No patient had physical neurological symptoms or signs.
A further patient, patient 4, with ﬁrst episode psychosis
identiﬁed after the prospective cohort, had NMDAR anti-
bodies (score 1.5). He was unwell for 4 months, partially
responsive and then relapsing despite treatment with anti-
psychotics. To reduce the levels of NMDAR antibodies he
received plasmapheresis and made a signiﬁcant clinical
improvement 3 weeks later, improving further with pred-
nisolone. He remains clinically and functionally improved
at 7 month follow up, on no antipsychotic medication. This
is the ﬁrst case description, to our knowledge, of a patient
with NMDAR antibodies and a purely psychiatric presen-
tation responding to immunotherapy.
These preliminary data show that some patients with
schizophrenia have potentially pathogenic autoantibodies
to relevant membrane proteins. Three of the patients had
NMDAR antibodies, which have been shown to reduce
NMDAR clusters in vivo [12], which mirrors that seen in
models of schizophrenia [13]. All of our antibody positive
cases (6.5% of 46) fulﬁlled DSMIV criteria for schizo-
phrenia and the patients were tested early in the course of
their illness. None of the chronic schizophrenia controls in
our large case series had NMDAR antibodies [9], but this
could be because NMDAR and VGKC antibodies sponta-
neously drop with time ([14]; SRI, AV unpublished data);
this suggests a critical early period of illness for detection
and treatment. We did not measure antibody in CSF, and
future prospective systematic studies of antibody in paired
serum and CSF will be informative.
The 46 patients in the Cameo cohort were given DSM-
IV diagnoses a year after intake to the service. Of these,
Fig. 1 HEK cells co-transfected with NR1, NR2B and EGFP cDNA
or transfected with EGFP cDNA alone. Serum of patient 1 bound to
the surface of unpermeabilised cells transfected with NMDARs, but
not EGFP alone. Healthy controls (Control) showed no binding
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12363% had a diagnosis of schizophrenia. Other psychotic
diagnoses were psychosis not otherwise speciﬁed (15%),
bipolar affective disorder (13%), schizoaffective disorder
(4%), major depression with psychosis (2%) and delusional
disorder (2%). It is therefore possible that the proportion of
cases with diagnoses of schizophrenia that have speciﬁc
antibodies is higher than the proportion described here.
However, there is signiﬁcant diagnostic instability in
patients with early psychosis, due to the threshold of
chronicity required for a diagnosis of schizophrenia. There
is also increasing evidence of shared heritability between
the psychotic disorders and consequently a move away
from the use of categorical diagnoses in those with psy-
chotic disorders.
There is a need for a systematic screen of available
neuronal surface antigens in ﬁrst episode psychosis and
schizophrenia to characterise the true prevalence of these
antibodies among different population groups, with impli-
cations for diagnosis, prognosis and treatment.
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